New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.68 0.11 +0.40%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. (PFE) Free cash flow

Alert me on Free cash flow

Pfizer Inc.'s free cash flow for fiscal 2025 was $9.1B, down 7.73% from $9.8B in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $11.8B. Over the past ten years it has ranged from $4.8B (fiscal 2023) to $29.9B (fiscal 2021); the current reading is higher than 18% of that period. Pfizer Inc. ranks 8th of 21 Drug Manufacturers General companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 $9.1B (7.73%)
FY2024 $9.8B 105.20%
FY2023 $4.8B (81.59%)
FY2022 $26.0B (12.85%)
FY2021 $29.9B 156.65%
FY2020 $11.6B 14.95%
FY2019 $10.1B (26.05%)
FY2018 $13.7B (6.13%)
FY2017 $14.6B 2.76%
FY2016 $14.2B 7.59%

Quarterly newest first

Period Free cash flow Change
Sep 2026 $4.8B 1,490.07%
Jun 2026 $302.0M (86.14%)
Mar 2026 $2.2B (51.61%)
Dec 2025 $4.5B 12.55%
43 more quarters

Against its own ten years

Low $4.8B High $29.9B
Ten-year median $13.2B
Current reading's percentile 18

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on PFE